| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Vistagen Therapeutics, Inc.$0.26
+0.01 (+3.53%)
C 42Pipeline Score Fair Value Biotech · Clinical
Market Cap
25.63 M
EPS
-
P/E Ratio
-
Value Trade
324.70 K
SEC Financials
Q1 2026Dilution Risk
Revenue
464.00 K
R&D Expenses
13.16 M
Operating CF
-16.61 M
Total Assets
48.56 M
Total Liabilities
13.04 M
Equity
35.52 M
D/E Ratio
12,345
1.09 %
Week
7.83 %
1 Month
9.68 %
3 Month
-85.53 %
6 Month
-99.18 %
5 Year
-99.96 %
All Time
Cash Data
Cash Position
45.40 M
Monthly Burn
5.54 M
Runway
7.3 mo
Burn Trend
SEC Filing
Jun 15, 2026
Overview
Volume
1.59 M
52 Week Range
0.43 - 5.14
% held by Insiders
14.96 %
% held by Institutions
22.18 %
Enterprise Value
-34.71 M
Total Shares
39.61 M
Short %
4.14 %
Float Shares
38.46 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vistagen Therapeutics, Inc.
334Total events
6Upcoming
70Tier-1 (high impact)
2011 – 2027Coverage
Upcoming catalysts 6
Event history 328
Jun 30, 2026
◆Topline ReadoutFasedienolClinical Data
Topline data from PALISADE-4 Phase 3 trial of Fasedienol for acute treatment of SAD
Social Anxiety Disordersource ↗
Jun 9, 2026
▲Safety Data UpdateFasedienolClinical Data
Achieved minimum ICH safety exposure recommendations across clinical program
Social Anxiety Disordersource ↗
May 18, 2026
◆Management ChangeCorporate
Appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 12, 2026
▲Interim AnalysisFasedienolTrial
Preliminary positive data in ongoing open-label extension portion of PALISADE-3 Phase 3 study
Social Anxiety Disordersource ↗
May 8, 2026
▲Last Patient Last VisitFasedienolTrial
Last patient visit completed in PALISADE-4 Phase 3 study of Fasedienol for acute treatment of social anxiety disorder
Social Anxiety Disordersource ↗
Apr 22, 2026
▲IND ClearancerefisoloneIND
FDA Study May Proceed letter for refisolone IND
Vasomotor Symptoms (Hot Flashes) due to Menopausesource ↗
Mar 2, 2026
◆Oral PresentationPresentation
Vistagen to present at 46th Annual TD Cowen Healthcare Conference
Feb 12, 2026
◆Quarterly UpdateCorporate
Fiscal Year 2026 Third Quarter Results and Corporate Update Conference Call
Dec 17, 2025
▼Primary Endpoint MissedFasedienolClinical Data
PALISADE-3 Phase 3 study of intranasal fasedienol did not demonstrate statistically significant improvement on primary endpoint
social anxiety disordersource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $46M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.8x
rNPV / MCap Top 60%
Micro Cap (rank 366 of 912)
Percentile RankVistagen Therapeutics, Inc. carries a moderate pipeline score (42/100), with $1.4B risk-adjusted pipeline value, led by Fasedienol in Social Anxiety Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fasedienol Small molecule | Social Anxiety Disorder (SAD) | Phase 3 | NCT06615557 | 49% | $464M | ACTIVE NOT_RECRUITING | 238 | AVERAGE | C (56) | Apr 1, 2027 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Fasedienol | Social Anxiety Disorder | Phase 3 | 2026-05-12 | preliminary positive data | Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Read More | |
Fasedienol | Social Anxiety Disorder | Phase 3 | 2026-05-12 | preliminary positive data | Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Read More | |
Fasedienol | Social Anxiety Disorder | Phase 3 | 2026-05-12 | preliminary positive data | Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VTGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VTGN▼ -70.3%on this news
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has announced topline and post-hoc data from the PALISADE-4 Phase 3 trial of Fasedienol, targeting the acute treatment of social anxiety disorder. The results are part of their ongoing research into effective therapies for this condition. Further details on the findings and implications were not disclosed in the announcement.
Read more →VTGN▲ +20.4%on this news
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen has reported its financial results for the fiscal year 2026, along with a corporate update. The details of the financial performance and any significant developments were not disclosed in the provided text. Further insights into the company's strategies or future plans were also not included.
Read more →VTGNVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has successfully achieved the minimum ICH safety exposure recommendations for its clinical program involving Fasedienol, aimed at treating acute social anxiety disorder. This milestone indicates the company's commitment to safety standards in its drug development process. The achievement may enhance the drug's prospects in clinical trials.
Read more →VTGN▲ +5.8%on this news
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Vistagen has appointed Angel S. Angelov, MD, MBA, as its new Chief Medical Officer. This leadership change is aimed at enhancing the company's strategic direction in drug development. Dr. Angelov brings extensive experience in clinical research and development to the role.
Read more →VTGN▼ -7.7%on this news
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has announced preliminary positive data from the ongoing open-label extension of the PALISADE-3 Phase 3 study for Fasedienol, aimed at treating social anxiety disorder. The results indicate a favorable response to the treatment, suggesting its potential effectiveness. This development marks a significant step in Vistagen's efforts to address mental health issues.
Read more →VTGNVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen has announced the completion of the last patient visit in the PALISADE-4 Phase 3 study, which evaluates fasedienol for the acute treatment of social anxiety disorder. This milestone is crucial for advancing the development of fasedienol as a potential treatment option. The study's results could significantly impact the management of social anxiety disorder.
Read more →VTGNVistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
Vistagen Therapeutics is under investigation for potential legal claims due to alleged false statements regarding its drug candidate fasedienol. Following the announcement of disappointing results from the PALISADE-3 Phase 3 study, the company's stock plummeted by more than 80%. Investors claim that Vistagen misled them about the drug's efficacy while concealing negative trial outcomes.
Read more →VTGNVistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Vistagen has received a 'Study May Proceed' letter from the FDA for its refisolone nasal spray, which is intended to treat vasomotor symptoms associated with menopause. This approval enables the company to continue its Phase 2 clinical development. Refisolone represents a non-hormonal and non-systemic approach to managing these symptoms.
Read more →VTGN▲ +5.6%on this news
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has alerted Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shareholders about an upcoming deadline to join a securities fraud class action lawsuit. The lawsuit, filed in the Northern District of California, claims that the company and certain executives misrepresented information regarding the Phase 3 PALISADE-3 trial of fasedienol, an investigational treatment for social anxiety disorder. Affected investors who purchased shares between April 1, 2024, and December 16, 2025, are advised of the deadline to file for lead plaintiff status by March 16, 2026.
Read more →VTGNVistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights – VTGN
Vistagen Therapeutics, Inc. is facing a class-action securities lawsuit due to alleged securities fraud that affected investors between April 2024 and December 2025. The lawsuit claims that the company disseminated misleading statements while concealing adverse facts about the Phase 3 trial of its investigational drug fasedienol for social anxiety disorder. Following disappointing trial results, Vistagen's stock price plummeted by over 80%. Investors are encouraged to contact Levi & Korsinsky for legal assistance before March 16, 2026.
Read more →VTGNVistagen to Participate in Upcoming Investor Conferences
Vistagen (Nasdaq: VTGN) has announced its participation in two upcoming investor conferences in March 2026. The company will engage in one-on-one meetings at the Leerink Healthcare Conference and host a fireside chat at the Stifel 2026 Virtual CNS Forum. Vistagen focuses on developing intranasal product candidates aimed at treating various mental health conditions.
Read more →VTGNVistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company, will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026. CEO Shawn Singh will provide a corporate overview during the event. The company is developing pherines, a new class of intranasal products aimed at treating various mental health conditions without traditional absorption methods.
Read more →VTGNVistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights – VTGN
Vistagen Therapeutics, Inc. is facing a class action securities lawsuit for alleged fraud related to its Phase 3 PALISADE-3 trial of fasedienol. The lawsuit claims that the company provided misleading positive statements while concealing negative information about the trial results. Following the announcement that the trial did not achieve its primary endpoint, Vistagen's stock plummeted by more than 80%. Investors are encouraged to contact Levi & Korsinsky LLP for more information regarding their rights.
Read more →VTGNVistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from
Vistagen reported its fiscal Q3 2026 financial results and provided updates on its clinical pipeline. The PALISADE-4 Phase 3 trial for fasedienol, targeting social anxiety disorder, is progressing with topline results expected in early 2026, following improvements based on previous trial data. However, the earlier PALISADE-3 trial did not meet its primary endpoint, although safety data remains favorable. The company continues with cash preservation measures and has seen a rise in both research and administrative expenses, contributing to a net loss.
Read more →VTGNVistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
Vistagen will host a conference call on February 12, 2026, to report its fiscal year 2026 third quarter results and provide a corporate update. The call will be accessible via webcast and dial-in, allowing investors to engage with the company's latest developments. Vistagen specializes in developing intranasal therapies aimed at treating various mental health conditions.
Read more →VTGNVISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Vistagen Therapeutics, Inc. on behalf of stockholders who acquired shares between April 1, 2024, and December 16, 2025. The lawsuit arises from allegations that Vistagen made materially false statements related to its Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder. Following the trial's failure to meet its primary endpoint, Vistagen's stock plummeted more than 80%. Investors have until March 16, 2026, to apply as lead plaintiffs in the case.
Read more →VTGNVISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has announced a class action lawsuit against Vistagen Therapeutics, Inc. (VTGN) for alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, aimed at treating social anxiety disorder. The action claims misrepresentations were made by the company and some senior officers about trial outcomes. Investors who purchased shares between April 1, 2024, and December 16, 2025, are invited to discuss their legal rights and options before the March 16, 2026, lead plaintiff deadline.
Read more →VTGNVistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights – VTGN
Vistagen Therapeutics, Inc. is being sued for securities law violations following the failure of its PALISADE-3 Phase 3 trial for fasedienol, a treatment for social anxiety disorder. The trial did not achieve its primary endpoint, leading to a significant stock price drop of over 80%. Shareholders who purchased VTGN shares during the specified class period are encouraged to register for the class action lawsuit. The deadline for registering and seeking lead plaintiff status is March 16, 2026.
Read more →VTGNVISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Vistagen Therapeutics, Inc. for allegedly providing misleading information related to its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder. The lawsuit claims that the company made overly positive statements while concealing material adverse facts about the trial's performance. Following the announcement of poor trial results, Vistagen's stock experienced a dramatic decline of more than 80%. Investors affected by this decline are encouraged to contact the law firm for potential legal action.
Read more →VTGNVISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. on behalf of shareholders who purchased its stock between April 1, 2024, and December 16, 2025. The lawsuit alleges misrepresentations related to the company's Phase 3 PALISADE-3 trial for fasedienol, an investigational candidate for treating social anxiety disorder. Shareholders are encouraged to take action by filing papers by March 16, 2026, if they wish to serve as lead plaintiffs.
Read more →VTGN▼ -80.3%on this news
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen announced that its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder failed to show a statistically significant improvement on its primary endpoint. The results were disappointing and inconsistent with earlier positive findings. The company is reviewing the study's implications and plans to seek FDA feedback while implementing cash preservation measures.
Read more →VTGN▼ -9.6%on this news· ran to -27% by day 1
Vistagen Appoints Nick Tressler as Chief Financial Officer
Vistagen has appointed Nick Tressler as Chief Financial Officer, effective December 1, 2025. Tressler brings over 20 years of experience in the biopharmaceutical sector, having previously held CFO roles at several companies. His appointment is expected to enhance Vistagen's strategic direction as the company approaches significant clinical milestones.
Read more →VTGNVistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
Vistagen presented promising data on PH80 at The Menopause Society 2025 Annual Meeting, highlighting its potential as a non-hormonal treatment for menopausal hot flashes. The findings suggest that PH80 effectively reduces autonomic nervous system activity without entering the bloodstream. This could provide a safer alternative for women experiencing vasomotor symptoms.
Read more →VTGN▼ -6.6%on this news
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Comp
Vistagen has announced its financial results for the second quarter of fiscal year 2026 and provided updates on its clinical trials. The PALISADE-3 Phase 3 trial for its treatment, fasedienol, is concluded, with topline results expected by the end of the year. The company aims to address social anxiety disorder, potentially providing the first FDA-approved acute treatment for this condition. A financial overview reveals increased expenses and net losses, yet Vistagen maintains a strong cash position and recently expanded its leadership team.
Read more →VTGN▲ +7.6%on this news
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder Topline results for the trial are expected by year end SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)
Vistagen announced the completion of its PALISADE-3 Phase 3 trial for fasedienol, aimed at treating social anxiety disorder. The topline results from this public speaking challenge study are expected by the end of the year, building on positive outcomes from the previous PALISADE-2 trial. The company emphasizes the potential of fasedienol to be the first acute treatment for the disorder, notably impacting over 30 million adults in the U.S. There is an ongoing open-label extension of the trial, and the FDA has granted Fast Track designation for fasedienol's development.
Read more →VTGNVistagen Appoints Paul Edick to its Board of Directors Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)
Vistagen has announced the appointment of Paul Edick to its Board of Directors, enhancing its governance team with his extensive industry experience. Edick, known for leadership in various biopharmaceutical roles, will contribute to the Audit and Compensation Committees. His appointment comes at a critical time as Vistagen progresses toward strategic growth and innovation in mental health treatments. The company remains focused on developing intranasal product candidates to address unmet needs in mental health care.
Read more →VTGN▼ -8.1%on this news
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quart
Vistagen, a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2026 and provided updates on its clinical programs. The Phase 3 PALISADE-3 trial of fasedienol for acute treatment of social anxiety disorder is expected to yield topline results in the fourth quarter of 2025, with PALISADE-4 results anticipated in the first half of 2026. The company remains optimistic about the potential for fasedienol to address a significant gap in treatment options for social anxiety disorder. Financially, Vistagen reported a net loss of $15.1 million for the quarter, although it maintains substantial cash reserves for ongoing developments.
Read more →VTGNVistagen Appoints Elissa Cote as Chief Corporate Development Officer Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role
Vistagen has appointed Elissa Cote as Chief Corporate Development Officer, effective immediately. With nearly 30 years of experience in business development and strategic planning, Cote aims to enhance Vistagen's clinical-stage pipeline, which focuses on innovative intranasal pherine candidates. The company is excited about her leadership, which is expected to drive growth and partnership opportunities. Cote's appointment is part of Vistagen's strategy to advance its novel therapies and address underserved mental health disorders.
Read more →VTGNVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of
Vistagen has reported its fiscal year 2025 financial results, highlighting strategic advancements in its PALISADE program for fasedienol, aimed at treating social anxiety disorder. The company anticipates topline results from the Phase 3 PALISADE-3 trial in Q4 2025, while PALISADE-4 results are expected in the first half of 2026. Despite a significant net loss and increased expenses, Vistagen continues to expand its pipeline of intranasal pherines addressing various mental health conditions, enhancing its strategic position in the biopharmaceutical market.
Read more →VTGN▼ -6%on this news
Document Vistagen on Track to Deliver Topline Data from Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of this Year Company's PALISADE-4 Phase 3 trial now expecte
Vistagen is progressing well with the PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder (SAD), with topline data expected in Q4 2025. Despite the anticipated delay in the PALISADE-4 trial results until H1 2026, there is strong enthusiasm from patients and doctors regarding these ongoing studies. Previous positive outcomes from the PALISADE-2 trial bolster confidence in the effectiveness of fasedienol. However, there are operational risks associated with the extended timelines of current trials, emphasizing the uncertainty inherent in drug development and regulatory approvals.
Read more →VTGN▼ -7.8%on this news
vistagencorporatepr Nasdaq: VTGN Pioneering neuroscience with nose-to-brain neurocircuitry
Vistagen Therapeutics is actively pioneering neuroscience through its innovative approach of nose-to-brain neurocircuitry. The company's registration-directed Phase 3 program for Social Anxiety Disorder is in progress, showcasing the potential of their unique intranasal product candidates known as pherines. Positive outcomes from recent clinical trials highlight the efficacy and safety of these candidates, which target various mental health conditions. However, Vistagen acknowledges the considerable risks involved in clinical development and the reliance on third-party partnerships, setting a cautious tone regarding future validation and market success.
Read more →VTGNVistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoin
Vistagen has reported its third quarter financial results for fiscal year 2025, highlighting the expected advancement of its fasedienol trials for social anxiety disorder towards top-line results. The company has also seen promising data from a Phase 2A study of PH284 in cancer cachexia. While the financial report indicates a substantial net loss and increased R&D expenses, Vistagen remains optimistic about its future prospects, supported by the FDA's Fast Track designation for fasedienol and several anticipated clinical readouts in 2025.
Read more →VTGNVistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Vistagen has been awarded a U.S. patent for its oral non-opioid product candidate AV-101, intended for treating neuropathic pain. The patent is set to last until at least 2034 and is part of a broader global strategy to advance AV-101's development and commercialization. Preclinical studies have shown that AV-101 has effects comparable to established pain medications but with a significantly improved side effect profile. Vistagen aims to explore potential partnerships to further its clinical development in treating pain and associated neurological disorders.
Read more →VTGNVistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine p
Vistagen announced positive results from an exploratory Phase 2A study of its investigational nasal spray PH284, aimed at addressing cancer cachexia. The study indicated that PH284 significantly improved subjective feelings of hunger among cancer patients compared to placebo. No serious adverse events were reported, and the treatment appeared safe and well-tolerated. This marks a promising advancement in Vistagen's neuroscience pipeline, as the company seeks to address unmet needs in appetite regulation for chronic disorders.
Read more →VTGNVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3
Vistagen (Nasdaq: VTGN) reported its financial results for the second quarter of fiscal year 2025, highlighting its ongoing progress in the PALISADE Phase 3 trials for fasedienol, aimed at treating social anxiety disorder. The company has initiated both PALISADE-3 and PALISADE-4 trials, with top-line results expected in 2025. Despite a net loss of $13 million for the quarter, Vistagen boasts a strong cash position of $97.6 million and a diverse pipeline that includes treatments for major depressive disorder and menopausal symptoms. The company's innovative approaches in neuroscience pave the way for potentially transformative therapies.
Read more →VTGNVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif.--(BUSINE
Vistagen has provided a corporate update along with its financial results for Q1 of FY 2025. The company is advancing its PALISADE Phase 3 program for its investigational nasal spray, fasedienol, targeted at treating Social Anxiety Disorder. Additionally, Vistagen is preparing for further trials for itruvone in major depressive disorder and PH80 for menopausal symptoms. Financially, the company posted a net loss, which increased compared to the previous year, partly due to rising research and administrative expenses.
Read more →VTGNVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE
Vistagen has reported substantial progress in its fiscal year 2024, notably achieving positive results from the PALISADE-2 Phase 3 trial for fasedienol, targeting social anxiety disorder, a previously underserved condition. The company is progressing with further trials, PALISADE-3 and PALISADE-4, expected to enhance its drug submission efforts. Financially, Vistagen has improved its cash position while reducing R&D expenses, although it still reports a net loss. The company is focused on securing FDA approval for its pioneering therapies based on unique mechanisms of action.
Read more →VTGNVistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
VistaGen Therapeutics announced that CEO Shawn Singh will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022. Singh will also provide a recorded presentation detailing the company's pipeline and milestones. VistaGen focuses on developing fast-acting treatments for anxiety and depression, with its lead candidate PH94B currently in Phase 3 trials.
Read more →VTGNVistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
VistaGen Therapeutics reported its third-quarter financial results and highlighted significant advancements in its clinical programs, particularly for PH94B in social anxiety disorder. The company is expanding its research to include other anxiety disorders and has initiated new trials for its depression treatment, PH10. Despite increased R&D expenses and net losses, the company remains committed to developing innovative therapies for mental health conditions.
Read more →VTGNVistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
VistaGen Therapeutics will hold a conference call on February 10, 2022, to report its financial results for the third quarter of fiscal year 2022. The call will review recent accomplishments and outline anticipated milestones. Investors and media can participate via a live audio webcast or telephone. The company focuses on developing innovative treatments for CNS disorders.
Read more →VTGNVistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
VistaGen Therapeutics will present at the Jefferies Virtual London Healthcare Conference on November 18, 2021. CEO Shawn Singh will engage in a fireside chat with Jefferies analyst Andrew Tsai. The presentation will be accessible via the company's website for 30 days post-conference, highlighting their commitment to CNS disorder treatments.
Read more →VTGNVistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan PH94B Phase 2A clinical program targeting additional potential anxiety indications launched in adjustment disorder with anxiety (
Read more →VTGN▼ -6.5%on this news
VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and o
Read more →VTGNVistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
VistaGen Therapeutics has announced the initiation of a Phase 2A clinical trial for PH94B, targeting Adjustment Disorder with Anxiety. This trial will run alongside ongoing Phase 3 studies for Social Anxiety Disorder. The company aims to explore PH94B's potential across various anxiety disorders, leveraging its unique mechanism of action that avoids systemic uptake.
Read more →VTGNVistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain
VistaGen Therapeutics announced promising preclinical data for PH94B, an investigational nasal spray for anxiety. The study showed that PH94B is primarily confined to the nasal passages, with minimal presence in the CNS, suggesting a unique mechanism of action. This could lead to fewer side effects compared to traditional therapies. The company is advancing PH94B through its PALISADE Phase 3 Program for Social Anxiety Disorder.
Read more →VTGNVistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
VistaGen Therapeutics has initiated PALISADE-2, a Phase 3 trial for PH94B, aimed at treating social anxiety disorder. This trial follows the ongoing PALISADE-1 and is designed to evaluate the efficacy and safety of PH94B, a rapid-onset nasal spray. Results from both trials are expected in mid to late 2022, with potential FDA submission in 2023.
Read more →VTGNVistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference
VistaGen Therapeutics will participate in Baird's 2021 Global Healthcare Conference on September 14. CEO Shawn Singh will lead a fireside chat, and the company will hold one-on-one meetings during the event. A live webcast of the presentation will be available on their website.
Read more →VTGNVistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anx
vtgn_ex991.htm EXHIBIT 99.1 VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressin
Read more →VTGNVistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and o
Read more →VTGNVistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other c
Read more →VTGNVistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors Ms. FitzPatrick, an internationally recognized corporate affairs executive, brings extensive healthcare consumer engagement, mar
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors Ms. FitzPatrick, an internationally recognized corporate affairs executive, brings extensive healthcare consumer engagement, marketing and public relations expertise to the Company's
Read more →VTGNVistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other c
Read more →VTGNVistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development o
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression SOU
Read more →VTGNVistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder Management to host corporate update conference
Read more →VTGNVistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and o
Read more →VTGNVistaGen Therapeutics Set to Join the Russell 2000® Index SOUTH SAN FRANCISCO, CALIF. –
VistaGen Therapeutics Set to Join the Russell 2000 SOUTH SAN FRANCISCO, CALIF. June 16, 2021 VistaGen Therapeutics, Inc. biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of
Read more →VTGNVistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022 SOUTH
Read more →VTGNVistaGen Therapeutics to Present at Two Investor Conferences in June
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central
Read more →VTGNVistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global l
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise for many successf
Read more →VTGNVistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as Vis
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its product candidates for anxiety a
Read more →VTGNVistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and o
Read more →VTGNVistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, de
Read more →VTGNVistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxie
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021 Multiple clinical studies anticipated to launch in Calendar 2021, notably pivota
Therapeutics Reports Fiscal 2021 Third Quarter Financial Results Provides Update on Expected Clinical Studies in Calendar Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxi
Read more →VTGNVistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Therapeutics Regains Full Compliance with Nasdaq Listing SOUTH SAN FRANCISCO, Calif., January 6, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go be
Read more →VTGNVistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and ot
Read more →VTGNVistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depress
Read more →VTGNVistaGen Therapeutics Announces Pricing of Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other
Read more →VTGNVistaGen Therapeutics Announces Proposed Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other
Read more →VTGNVistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as V
VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Dr. Monti developed the inn
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress -- Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Proceeds fro
Read more →VTGNVirtual Annual Meeting of Stockholders Closing Remarks from Shawn K. Singh, JD, Chief Executive Officer and Director Thank you to the stockholders who participated in this, our first, virtual annual meeting, as well as t
Annual Meeting of Stockholders Closing Remarks from Shawn K. Singh, JD, Chief Executive Officer you to the stockholders who participated in this, our first, virtual annual meeting, as well as those who submitted their proxies prior to the meeting but were unable to like to b
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public O
Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Meeting with the FDA Sets Key Aspects of Piv
Read more →VTGNVistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., August 2, 2020 -- (BUSINESS WIRE) VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for
Read more →VTGNVistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder Company Reaches Consensus with FDA on Key Aspects
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder Company Reaches Consensus with FDA on Key Aspects of Novel Pivotal Phase 3 Study Agency Guidance May Pro
Read more →VTGNVistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update VistaGen Eligible to Receive up to $177 Million, Including Upfront and Potential Milestone Payments, in Addition to Royalties, under
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides Eligible to Receive up to $177 Million, Including Upfront and Potential Milestone Payments, in Addition to Royalties, under PH94B License in Key Asian Markets Announced Subsequent to Fiscal 2020 SOUTH SAN FRA
Read more →VTGNVistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia Collaboration intended to support
Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets Agreement includes $
Read more →VTGNVistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior De
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple Novel Cocrystal Form of AV-101 Administered with May Have Superior Delivery, an Enhanced Therapeutic and Additional Intellectual Property Protection S
Read more →VTGNVistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) The Proposed Phase 2A
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program The Proposed Phase 2A Open-label Study will be Conducted in New SOUTH SAN FRANCISCO,
Read more →VTGNVistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19 Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19 Proposed Phase 2 Study to Take Place in New York City Under U.S. Coronavirus Treatment Acceleration Program SOUTH SAN FRANCISCO, Calif., April 28, 2020 VistaGen Therapeutics (NASDA
Read more →VTGNVistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million SOUTH SAN FRANCISCO, Calif., March 25, 2020 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression a
Read more →VTGNVistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Anti
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Saf
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline SOUTH SAN FRANCISCO, Calif., February 13, 2020 VistaGen Therapeutics clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CN
Read more →VTGNVistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients Company also Receives a Notice of Allowance from the USPTO f
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia
Read more →VTGNU.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder South San Francisco, Calif., (D
Read more →VTGNVistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder SOUTH SAN FRANCISCO, Calif., November 14, 2019 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview SOUTH SAN FRANCISCO, Calif., November 7, 2019 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for ce
Read more →VTGNVistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease SOUTH SAN FRANCISCO, Calif., October 28, 2019 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopha
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial SOUTH SAN FRANCISCO, Calif., August 13, 2019 - VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and
Read more →VTGNVistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray Previously completed Phase 2a clinical study of PH10 demonstrated significant antidepressant
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal completed Phase 2a clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only
Read more →VTGNVistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease, without the Psychological Side Effects and Safety Concerns of Aman
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease, without the Psychological Side Effects and Safety Concerns of Amantadine Significant reduction of levodopa-induced dyskin
Read more →VTGNPositive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder PH94B has potential to be the First FDA-Approved P
Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings
Read more →VTGNCORPORATE PRESENTATION Untitled Document
CORPORATE PRESENTATION Untitled Document
Read more →VTGNVistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, t
Read more →VTGNVistaGen Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, t
Read more →VTGNVistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, t
Read more →VTGNVistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10 SOUTH SAN FRANCISCO, Calif., Feb 13, 2019 - VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depressio
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for treating depression and other central nervous system (CNS) diseases and disorders with hig
Read more →VTGNVistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that S
Read more →VTGNAV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
Stimulates the Formation of New Brain Cells in Nonclinical SOUTH SAN FRANCISCO, Calif., Jan 31, 2019 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders wi
Read more →VTGNVistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors SOUTH SAN FRANCISCO, Calif., Jan. 15, 2018 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation me dicines for cent
Read more →VTGNPRESENTATION Untitled Document
PRESENTATION Untitled Document
Read more →VTGNVistaGen Therapeutics to Present at 11th Annual Biotech Showcase
SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that i
Read more →VTGNVistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
New Hong Kong patent complements counterpart patents previously issued in China, Europe and the U.S. SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicine
Read more →VTGNVistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results South San Francisco, Calif.
VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial South San Francisco, Calif., October 29, 2018 VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseas
Read more →VTGNVistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demo
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a PH10 demonstrated in Phase 2a study
Read more →VTGNVistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced th
Read more →VTGNVistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced th
Read more →VTGNVistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain Designation highlights serious unmet need for new treatment options for patients sufferin
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain Second FDA Fast Track designation for
Read more →VTGN1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29
1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29-
Read more →VTGNVistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder ● Phase 3-ready asset expands VistaGen's CNS pipe
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder Phase 3-ready asset expands VistaGen's CNS pipeline and complements its neuropsychiatry focus on Major Depressiv
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results
SOUTH SAN FRANCISCO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unme
Read more →VTGNVistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen's AV-101 for Potential Anti-Suicidal Effects in Veterans Veterans from Operation Enduring Freedom, Operation Iraqi Fre
Therapeutics and Baylor College of Medicine on First-Step Study to Test VistaGen's AV-101 for Potential Anti-Suicidal Effects in Veterans Veterans from Operation Enduring Freedom, Operation Iraqi Freedom and Operation New Dawn to Participate in Study South San Francisco, Cal
Read more →VTGNVistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights AV-101, VistaGen's Oral NMDA Receptor Modulator, Granted FDA Fast-Track Designation for Major Depressive Disorder Key
VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights AV-101, VistaGen's Oral NMDA Receptor Modulator, Granted FDA Fast-Track Designation for Major Depressive Disorder Key AV-101 Patents Issued in U.S., Europe and Asia ELEVATE,
Read more →VTGNVistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101
SOUTH SAN FRANCISCO, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders, today announced t
Read more →VTGNBlueprint VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 South San Francisco, CA (
VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 South San Francisco, CA (June 13, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and o
Read more →VTGNVistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
Patent Covers Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depr
Read more →VTGNSecconnect.com VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders Patent Covers Methods for Producing Blood Cells, Platelets and Bone Mar
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders Patent Covers Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells South San Francisco, CA (June 11, 2018) - VistaGen Therape
Read more →VTGNVistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage South San Francisco, CA (
VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage South San Francisco, CA (May 23, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmac
Read more →VTGNVistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101 South San Francisco, CA (
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101 South San Francisco, CA (May 2, 2018) VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines f
Read more →VTGNVistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 South San Francisco, CA (
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 South San Francisco, CA (April 10, 2018) Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other centr
Read more →VTGNVistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder South San Francisco, CA (
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major South San Francisco, CA (April 5, 2018) VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system
Read more →VTGNVistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 South San Francisco, CA (
VistaGen Therapeutics Receives a Notice of Allowance for Another U.S. Patent Covering Oral Formulations of AV-101 South San Francisco, CA (March 19, 2018) Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for dep
Read more →VTGNVistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 South San Francisco, CA (
VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 South San Francisco, CA (March 7, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation med
Read more →VTGNVistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results South San Francisco, CA (
VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial South San Francisco, CA (February 12, 2018) Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous
Read more →VTGNVistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder South San Francisco, CA (
VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive South San Francisco, CA (January 29, 2018) Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new gen
Read more →VTGNVistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder South San Francisco, CA (
VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder South San Francisco, CA (January 3, 2018) Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation me
Read more →VTGNVistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock South San Francisco, CA (
VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock South San Francisco, CA (December 13, 2017) Therapeutics, Inc. (NASDAQ: VTGN) ( VistaGen or the Company ), a clinical-stage biopharmaceutical company focused
Read more →VTGNVistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer SOUTH SAN F
Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Producing Blood Cells, Platelets and Bone Marrow Stem to Treat Autoimmune Disorders and Cancer SOUTH SAN FRANCISCO, CA--(Marketwired - December 08, 2017) - VistaGen Therapeutics Inc. (VTGN), a clinical-stage bioph
Read more →VTGNVistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101 South San Francisco, CA (
VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101 South San Francisco, CA (December 6, 2017) Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and othe
Read more →VTGNVistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, CA -- (Marketwired –
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, CA -- (Marketwired November 9, 2017) -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing ne
Read more →VTGNSecconnect.com VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression South San Francisco, CA (
VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression South San Francisco, CA (November 6, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression
Read more →VTGNVistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder South San Francisco, CA (
VistaGen Announces FDA Authorization to Initiate Phase 2 of AV-101 for Major Depressive Disorder South San Francisco, CA (October 26, 2017) VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines fo
Read more →VTGNVistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101 South San Francisco, CA (
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101 South San Francisco, CA (September 28, 2017) Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on develop
Read more →VTGNVistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock South San Francisco, CA (
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock South San Francisco, CA (August 31, 2017) VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ( VistaGen or the Company ), a clinical-stage biopharmaceutical company focused on
Read more →VTGNVistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, CA -- (Marketwired –
VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update SAN FRANCISCO, CA -- (Marketwired August 14, 2017) -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new genera
Read more →VTGNVistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmun
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer South San Francisco, CA (August 8
Read more →VTGNVistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, CA -- (Marketwired –
VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate SAN FRANCISCO, CA -- (Marketwired June 29, 2017) -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for de
Read more →VTGNBlueprint VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement SOUTH SAN FRANCISCO, CA -- (Marketwired
VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement SAN FRANCISCO, CA -- (Marketwired - May 1, 2017) -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression
Read more →VTGNVistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain
VistaGen Therapeutics Announces Peer-Reviewed Journal of Pain Highlighting AV-101's Potential for Treating SAN FRANCISCO, CA -- (Marketwired) -- 04/27/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generat
Read more →VTGNVistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 South San Francisco, CA (
VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 South San Francisco, CA (March 29, 2017) Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines
Read more →VTGNVistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, March 10, 2017 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc. (Nasdaq:VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, will visit the Nasdaq MarketSite in T
Read more →VTGNVistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics VistaGen to receive upfront payment of $1.25M South San Francisco, CA (
VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Cell Technologies to BlueRock Therapeutics VistaGen to receive upfront payment of $1.25M South San Francisco, CA (December 14, 2016) Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focu
Read more →VTGNVistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update South San Francisco, CA (
VistaGen Therapeutics Reports Second Quarter 2017 Financial Results South San Francisco, CA (November 14, 2016) VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other centra
Read more →VTGNVistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones - Company poised to achieve multiple key corporate, business, clinical and regulatory milestones in the near-term - South San Francisco, CA (
VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones - Company poised to achieve multiple key corporate, business, clinical and regulatory milestones in the near-term - South San Francisco, CA (September 22, 2016) - VistaGen Therapeutics Inc. (NASDAQ:
Read more →VTGNSecconnect.com VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer Former Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals to lead clin
VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer Former Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals to lead clinical development of AV-101 in major depressive disorder (MDD) and addition
Read more →VTGNVistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering - Company Uplisting to NASDAQ Capital Market Under New Ticker "VTGN" Effective
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering - Company Uplisting to NASDAQ Capital Market Under New Ticker "VTGN" Effective South San Francisco, CA (May 10, 2016) - VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical
Read more →VTGNSecconnect.com VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors South San Francisco, CA (
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors South San Francisco, CA (March 30, 2016) - VistaGen Therapeutics Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing i
Read more →VTGNVistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression Sanjay Mathew, M.D., expert in the psychopharmacological management of depressive
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression Sanjay Mathew, M.D., expert in the psychopharmacological management of depressive and anxiety disorders, appointed as Board member Thomas L
Read more →VTGNSecconnect.com 2015 Letter to Stockholders February 2016 Dear Fellow Stockholders: 2015 was a year marked by significant accomplishments on the clinical, regulatory and operational fronts which we believe will enable Vis
2015 Letter to Stockholders Dear Fellow Stockholders: 2015 was a year marked by significant accomplishments on the clinical, regulatory and operational fronts which we believe will enable VistaGen to achieve key milestones and position the Company for a strong 2016 and beyond.
Read more →VTGNSecconnect.com VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder S outh S an F rancisco, CA - November 3 , 2015 - VistaGen Therapeutics, Inc. (
VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder South San Francisco, CA - November 3, 2015 - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developi
Read more →VTGNFavorable Data on VistaGen Therapeutics' AV-101 for Major Depressive Disorder Published in Peer-reviewed Journal of Pharmacology and Experimental Therapeutics Pre-clinical Study Results Show Equal Efficacy and Improved S
Favorable Data on VistaGen Therapeutics' AV-101 for Major Depressive Disorder Published in Peer-reviewed Journal of Pharmacology and Experimental Therapeutics Pre-clinical Study Results Show Equal Efficacy and Improved Safety Profile Compared with Ketamine South San Francisco,
Read more →VTGNSecconnect.com VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder Phase 2 Clinical Study in Major Depressive Disorder Expected to Commence at
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder Phase 2 Clinical Study in Major Depressive Disorder Expected to Commence at NIH in 3Q 2015 SOUTH SAN FRANCISCO -- (Marketwired: July 1, 2015) - Vis
Read more →VTGNINVESTOR PRESENTATION ex99-1.htm
INVESTOR PRESENTATION ex99-1.htm
Read more →VTGN, DATED AUGUST 13, 2014 ex99-1.htm VistaGen Announces Reverse Stock Split
VistaGen Announces Reverse Stock Split SOUTH SAN FRANCISCO, CA - August 13, 2014 (MARKETWIRE via COMTEX) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for
Read more →VTGNVistaGen Provides Update on $36 Million Strategic Financing Agreement
VistaGen Provides Update on $36 Million Strategic Financing Agreement SOUTH SAN FRANCISCO, CA - June 28, 2013 (MARKETWIRE via COMTEX) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxico
Read more →VTGNVistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research's 11th Annual Meeting
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 17, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D and L
Read more →VTGNVistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
SOUTH SAN FRANCISCO, CA--(Marketwired - May 7, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-
Read more →VTGNEx hibit 99.1 VistaGen Announces $36 Million Strategic Financing Agreement Proceeds will accelerate stem cell technology-based drug rescue, predictive toxicology and drug metabolism programs
VistaGen Announces $36 Million Strategic Financing Agreement Proceeds will accelerate stem cell technology-based drug rescue, predictive toxicology and drug metabolism programs SOUTH SAN FRANCISCO, CA - April 10, 2013 (MARKETWIRE via COMTEX) - VistaGen Therapeutics, Inc. (OTCQ
Read more →VTGNVistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 12, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to Live
Read more →VTGNVistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 11, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces it will feature key developments involving Ca
Read more →VTGNSecconnect.com VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screeni
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screening System for Heart Toxicity SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 1
Read more →VTGNVistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 4, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, and Celsis In Vitro Technologies ("Celsis"), the premier globa
Read more →VTGNSecconnect.com VistaGen Therapeutics Enters Strategic Collaboration with Celsis IVT to Further Advance LiverSafe 3D Companies structure collaboration to focus on development and characterization of VistaGen ' s human plu
VistaGen Therapeutics Enters Strategic Collaboration with Celsis IVT to Further Advance LiverSafe 3D Companies structure collaboration to focus on development and characterization of VistaGen's human pluripotent stem-cell derived liver cells SOUTH SAN FRANCISCO, CA - March 4, 2
Read more →VTGNVistaGen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
SOUTH SAN FRANCISCO, CA--(Marketwire - Jan 23, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Pha
Read more →VTGNVistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
SOUTH SAN FRANCISCO, CA--(Marketwire - Jan 22, 2013) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of
Read more →VTGNVistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine (CCRM) Consortium
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 3, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre f
Read more →VTGNVistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D(TM)
SOUTH SAN FRANCISCO, CA--(Marketwire - Nov 13, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced a significant advance in its
Read more →VTGNVistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
SOUTH SAN FRANCISCO, CA--(Marketwire - Nov 7, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, and Duke University, one of the country's pre
Read more →VTGNVistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 16, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism scre
Read more →VTGNVistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund
SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 6, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism scree
Read more →VTGNSecconnect.com VistaGen CEO Issues Update Letter to Stockholders SOUTH SAN FRANCISCO, CA - ( Marketwire
VistaGen CEO Issues Update Letter to Stockholders SOUTH SAN FRANCISCO, CA-(Marketwire - May 14, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockh
Read more →VTGNVistaGen Therapeutics Enters Strategic Drug Screening Collaboration With Vala Sciences
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 21, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, and Vala Sciences, Inc., a biotechnology company developing and selling next-gen
Read more →VTGNVistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 5, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, and Duke University, one of the country's premier academic research institutions, have entered int
Read more →VTGNVistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor
ATLANTA, GA--(Marketwire - Feb 21, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implem
Read more →VTGNVistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates Company Identifies Initial Top 10 Candidates for Formal Drug Rescue Programs Beginning in Mid-2012 SOUTH SAN FRANCISCO, CA -- (Marketwire - 0
VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates Company Identifies Initial Top 10 Candidates for Formal Drug Rescue Programs Beginning in Mid-2012 SOUTH SAN FRANCISCO, CA -- (Marketwire - 02/14/12) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQ
Read more →VTGNVistaGen Therapeutics Increases Its Drug Rescue Opportunities With Right-of-First-Offer Agreement With Cato BioVentures and Cato Research
SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 8, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has signed a strategic drug rescue agreement with Cato BioVentures and Cato Research. The comp
Read more →VTGNSecconnect.com VistaGen Therapeutics and Synterys Sign Strategic Medicinal Chemistry Collaboration Agreement for Drug Rescue Collaboration to focus on leveraging VistaGen ' s stem cell-based technology to develop safer,
VistaGen Therapeutics and Synterys Sign Strategic Medicinal Chemistry Collaboration Agreement for Drug Rescue Collaboration to focus on leveraging VistaGen's stem cell-based technology to develop safer, drug rescue variants of once-promising drug candidates South San Francisc
Read more →VTGNVistaGen Therapeutics and Synterys Sign Strategic Medicinal Chemistry Collaboration Agreement for Drug Rescue
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 7, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, and Synterys, Inc., a medicinal chemistry and collaborative drug discovery company, have entere
Read more →VTGNVistaGen Therapeutics and University Health Network (Toronto) Extend Broad Stem Cell Alliance and Expand Scope of Collaborative Research SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/17/11 -- VistaGen Therapeutics, Inc.
VistaGen Therapeutics and University Health Network (Toronto) Extend Broad Stem Cell Alliance and Expand Scope of Collaborative Research SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/17/11 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell t
Read more →VTGNVistaGen Therapeutics and University Health Network (Toronto) Extend Broad Stem Cell Alliance and Expand Scope of Collaborative Research
SOUTH SAN FRANCISCO, CA--(Marketwire - Nov 17, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, and the University Health Network (UHN), one of Canada's largest research hospitals, have expa
Read more →VTGNVistaGen Therapeutics Reports Identification of Cell Surface Marker That Permits High-Yield Purification of Human Pluripotent Stem Cell-Derived Cardiomyocytes
SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 25, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, announces the publication of original research funded by the Company that identifies an antibo
Read more →VTGNVistaGen Therapeutics Presents Highlights of Its Human Stem Cell-Derived "Micro-Heart" Cardiotoxicity Assay at NIH Symposium on Cardiovascular Regenerative Medicine
SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 5, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, announces a poster presentation of its research and development activities leading to validatio
Read more →VTGNVistaGen Therapeutics Expands Key Stem Cell Technology Patent Estate Supporting Its Drug Rescue and Cell Therapy Programs
SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 28, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, announces the issuance of two additional United States patents supporting its therapeutic and
Read more →VTGNVistaGen Therapeutics Reports Advances in Its Pancreatic Cell and Regenerative Medicine Programs
SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 26, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, announces the publication of its original research demonstrating the use of pluripotent stem c
Read more →VTGNVistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives
SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 14, 2011) - VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company primarily focused on applying stem cell technology for drug rescue and cell therapy, today provides a comprehensive update on the Company's strategic plan to
Read more →Competitive Position
How VTGN ranks across every disease it competes inCompetitive Position is a premium feature
See how VTGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial